Format
Sort by
Items per page

Send to

Choose Destination

Best matches for chronic fatigue "hepatitis c":

Search results

Items: 1 to 20 of 568

1.

Real life Egyptian experience of Daclatasvir plus Sofosbuvir with Ribavirin in naïve difficult to treat HCV patients.

Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M.

Infect Disord Drug Targets. 2018 Jul 16. doi: 10.2174/1871526518666180716141806. [Epub ahead of print]

PMID:
30009715
2.

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.

Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N.

Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192. [Epub ahead of print]

PMID:
29994874
3.

Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C.

Evon DM, Golin CE, Ruffin R, Ayres S, Fried MW.

Pilot Feasibility Stud. 2018 Jun 27;4:92. doi: 10.1186/s40814-018-0285-5. eCollection 2018.

4.

Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/HIV Coinfection in a Community Care Setting.

Vijay G, Rajib HM, Mazin K, Sandipan C, Osama M, Sumit D, Amrendra Kumar M, Arshpal G, Pavani G, Ramakrishnaiah S, Khalid M, Jagannath S, Mohammed M, Smruti M.

Gut Liver. 2018 Jun 22. doi: 10.5009/gnl18004. [Epub ahead of print]

5.

Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ.

Hepatol Int. 2018 Jun 21. doi: 10.1007/s12072-018-9879-5. [Epub ahead of print] Review.

PMID:
29931590
6.

Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.

Younossi ZM, Stepanova M, Reddy R, Manns MP, Bourliere M, Gordon SC, Schiff E, Tran T, Younossi I, Racila A.

Liver Int. 2018 Jun 12. doi: 10.1111/liv.13900. [Epub ahead of print]

PMID:
29893462
7.

Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.

Thiam A, Conway B.

Drugs Today (Barc). 2018 Apr;54(4):237-244. doi: 10.1358/dot.2018.54.4.2795154.

PMID:
29869645
8.

Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.

Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP.

Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print]

PMID:
29859740
9.

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.

Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG.

Korean J Intern Med. 2018 May 25. doi: 10.3904/kjim.2017.368. [Epub ahead of print]

10.

Anemia, Screening.

Freeman AM, Morando DW.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Apr 23.

11.

Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4.

Abdel-Moneim A, Aboud A, Abdel-Gabaar M, Zanaty MI, Ramadan M.

Hepatol Int. 2018 May 12. doi: 10.1007/s12072-018-9868-8. [Epub ahead of print]

PMID:
29754329
12.

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C.

de Medeiros LPJ, Lima MBC, Pires MMA, Maciel AMA, Medeiros RBV, Donadel MD, Pereira IMB, Leão FM, Pires LEACL, Rzetelna H, Brandão-Mello CE.

Osong Public Health Res Perspect. 2018 Apr;9(2):50-58. doi: 10.24171/j.phrp.2018.9.2.03.

13.

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting.

Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S.

Gastroenterology Res. 2018 Apr;11(2):130-137. doi: 10.14740/gr999w. Epub 2018 Apr 7.

14.

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.

Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W.

Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906. [Epub ahead of print]

15.

Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.

Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH.

Hepatol Int. 2018 Apr 16. doi: 10.1007/s12072-018-9861-2. [Epub ahead of print]

PMID:
29663115
16.

A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.

Li C, Hu J.

Medicine (Baltimore). 2018 Apr;97(15):e0416. doi: 10.1097/MD.0000000000010416.

17.

Probable fidaxomicin-induced pancytopenia.

Axtell S, Shokoya A, Yocum C.

Am J Health Syst Pharm. 2018 Apr 15;75(8):532-535. doi: 10.2146/ajhp170239.

PMID:
29626003
18.

Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.

Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M.

Dig Dis Sci. 2018 May;63(5):1341-1347. doi: 10.1007/s10620-018-5005-8. Epub 2018 Mar 15.

PMID:
29546644
19.

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.

Heo YA, Deeks ED.

Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.

PMID:
29546556
20.

Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection.

Oriolo G, Egmond E, Mariño Z, Cavero M, Navines R, Zamarrenho L, Solà R, Pujol J, Bargallo N, Forns X, Martin-Santos R.

Aliment Pharmacol Ther. 2018 May;47(9):1238-1252. doi: 10.1111/apt.14594. Epub 2018 Mar 14. Review.

PMID:
29536563

Supplemental Content

Loading ...
Support Center